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A single institution case series of adenovirus infections after allogeneic hematopoietic stem cell transplantation is presented
to highlight the consideration for adenovirus infections as an etiology in patients with rapid hepatic or other sudden organ
deterioration in the setting of apparent GVHD stabilization. The series also highlights that survival is limited with these infections
often due in part to concomitant opportunistic infections. In addition, the pathophysiological events, such as GVHD and hepatic
dysfunction, may complicate the clinical picture and delay therapy of an opportunistic infection. This is particularly true for
adenoviral infections as they also have a distinct clinical picture in immunocompromised patients when compared to immune
competent patients. Adenovirus infections also have the additional challenge that its treatment, cidofovir, has associated toxicities
that can delay its administration. Recent developments has yielded an assay that can be used in the early detection and for serial
determinations of adenovirus in patients with advanced GVHD, as well as a new therapeutic agent currently undergoing clinical
trials.
1.Introduction
In the majority of immune competent patients, adenovirus
infections are often limited to single organ presentation
associated with its strong tissue tropism to epithelial surfaces
[1, 2]. However in immunocompromised patients, dissemi-
natedinfectionsarecommonandcanbediﬃculttodiagnose
due to the often associated multiorgan dysfunction arising
secondary to the pathophysiological processes that involved
the allogeneic transplant [3]. The diagnostic diﬃculties
of identifying this opportunistic infection are magniﬁed
in patients who are experiencing multiorgan failure with
advanced grade acute graft versus host disease (GVHD),
often with concomitant CMV and/or fungal infections [4,
5]. The dilemma in diagnosis of the infection can also
be challenging when dealing with complications of hepatic
failure secondary to GVHD [6, 7]. As well, in the past due
to the lack of adequate diagnostic studies, identiﬁcation of
adenovirus was compromised although it has now improved
with molecular screening tools. In this highlighted case
history, we provide an illustration of the critical impact
that adenovirus infections have on immunocompromised
patients with advanced GVHD and propose the recommen-
dation that adenovirus must be considered in patients with
rapid hepatic or other sudden organ deterioration in the
setting of apparent stabilization of GVHD.2 Advances in Hematology
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Figure 1:(a)TimecourseofASTelevationafterallogeneictransplant,(b)hepaticnecrosiswithintraparenchymalhemmorhage(H&E,4x),
(c) hepatocyte nuclei with marked variation in size, with intranuclear inclusions (H & E, 40x), (d) immunohistochemistry stain—positive
foradenovirus(40x),(e)electronmicrographofintranuclearadenovirusparticles(14,000x),(F)high-resolutionelectronmicrographimage
of adenovirus particles (36,000x).
2. CaseReport and Series
The highlighted patient (number 1 in the following tables)
is a 67 years old male with a history of multiply relapsed
follicular lymphoma who underwent nonmyeloablative sib-
ling allogenic peripheral blood stem cell transplant. He
was admitted on day +44 for suspected acute graft-
versus-host disease (aGVHD) with new onset large volume
diarrhea with renal insuﬃciency. The patient proceeded
to have a two-month hospital stay notable for incom-
plete control of grade III GVHD despite interventions
with high-dose steroids, tacrolimus, mycophenolate mofetil,
and denileukin diftitox. The course was complicated by
coagulase-negative Staphylococcus bacteremia, CMV reac-
tivation, and suspected Aspergillus pneumonia requiring
antibiotics, ganciclovir, and antifungal therapy, respectively.
During a period of apparent convalescence, the patient
developed rapid onset of hepatic failure. Diﬀerential diag-
nosis included infection, medication toxicity, and hepatic
GVHD. Intervention was futile and the patient succumbed
in ﬁve days, during which, the AST and ALT increased
from 80 and 137 U/L to 6163 and 3626 U/L, respectively,
(Figure 1(a)).
Autopsyresultsrevealedacutehepaticnecrosissecondary
to disseminated adenovirus infection and also demonstrated
coinfection with Aspergillus nodules identiﬁed within the
lungs (Figures 1(b) and 1(c)). Immunohistochemical stain-
ing for adenovirus was positive in the lamina propria of
the small and large intestine, liver, and lung (Figure 1(d))
with conﬁrmation by electron microscopy of the high viral
load (Figures 1(e) and 1(f)). In retrospect, the clinical
time course was suggestive of infection with adenovirus
[4], although initial clinical impressions were that the
patient was developing rapidly progressive hepatic GVHD.
Interestingly, at the time of autopsy, a two-state (Oregon
and Washington) public health advisory warning regard-
ing severe respiratory infection due to adenovirus, in
particular serotype 14, was issued [8]. Conﬁrmation of
the serotype in this patient was not possible but con-
cerns were raised regarding hospital acquired adenoviral
infection.
With these considerations, we reviewed all other aden-
ovirus infections experienced by patients undergoing allo-
geneic transplants in our center in the past ﬁve years (Tables
1and2).Allsixpatients,includingpatient1describedabove,
had been heavily pretreated prior to proceeding to theirAdvances in Hematology 3
Table 1: Patient Demographics. Cy/TBI: Cyclophosphamide/Total Body Irradiation, PBSCT: Peripheral Blood Stem Cell Transplant, MUD:
Matched unrelated donor, CML: Chronic Myeloid Leukemia, ALL: Acute Lymphocytic Leukemia, CML: Chronic Myeloid Leukemia, M:
male, F: female.
Age/Gender Disease Pretransplant Therapy Conditioning
Therapy
Type of
Transplant
GVHD
Prophylaxis GVHD Onset Max Grade
GVHD
1 67/M Follicular
Lymphoma
R/CHOP
R/DHAP
Fludarabine
Busulfan
Fludarabine
TBI
Allogeneic
PBSCT
MMF
Cyclosporine
Day +38
Skin, gut
Stage II
III
2 44/M Follicular
Lymphoma
R/CHOP
FND-R
Rituxan +
Bortezomib
Genmab Anti-CD20 Ab
Study
R-ICE salvage
Cy/TBI
Sibling
Allogeneic
PBSCT
Steroids
Methotrexate
Day +20 gut
and liver
Stage III
IV
3 39/M
CML with
T315I
mutation
Dasatinib
Imatinib
3+7
HIDAC
3+7
Cy/TBI MUD PBSCT
Steroids
Methotrexate
Cyclosporine
Day +19
Skin, gut, and
conjunctivae
Stage IV
IV
4 57/F Follicular
Lymphoma
R/CHOP
RICE
RESHAP
RICE
Cy/TBI Allogeneic
PBSCT
Steroids
Methotrexate
Cyclosporine
Day +30 Gut
Stage II III
5 42/F ALL Hyper CVAD Cy/TBI MUD
Steroids
Methotrexate
Cyclosporine
Day +360
Skin, gut
Stage IV
IV
6 49/M Multiple
Myeloma
Local Radiation
Lenalidomide
Bortezomib/Doxil/Dex
Carmustine
Etoposide
Cytarabine
Mephalan
Allogeneic
PBSCT
Steroids
Methotrexate
Cyclosporine
Day +26 gut
Stage II III
Table 2: Clinical course of Adenovirus infections.
Clinical
Presentation
Diagnosis of
Adenovirus
Therapy for
Adenovirus
Viral Outcome
(copies/ml)
Current
Status
1 Hepatitis
Day +98 Autopsy None Death Death
Day +101
2 Pulmonary
Day +180
Serum∗ and
BAL PCR
Cidofovir 1mg/kg
QOD ×7d o s e s
IVIG ×1d o s e
45,000→ 2,000→
negative
ECOG 4
Day +392
3 Pulmonary
Day +64 Serum∗ PCR Cidofovir 4mg/kg
qweek ×3d o s e s
560,000→ 25,700→
death prior to repeat
Death
Day +92
4 Cystitis
Day +168
Serum, CSF,
Urine∗ PCR
Cidofovir 1mg/kg
QOD ×3d o s e s
IVIG ×2d o s e s
2mill→ 15mill →
800→ no repeat
ECOG 1
Day +434
5 Cystitis
Day +218
Urine∗,a n d
Serum PCR
Cidofovir 1mg/kg
QOD ×7d o s e s
370,000→ 1,000→
no repeat
Death
Day +1020
6 Pulmonary
Day +30
Serum∗,B A L ,
and Stool PCR
Cidofovir 1mg/kg
QOD ×5d o s e s
IVIG ×3
18,000→ death prior
to repeat
Death
Day +46
∗used to determine viral outcome.4 Advances in Hematology
allogeneic transplantation procedure. Five of the six patients
underwent conventional conditioning with a three-drug
GVHDprophylaxisschedule.FivepatientsdevelopedGVHD
early in their treatment course. Notably, the highlighted
patient received an unrelated allogeneic reduced intensity
transplantation procedure with cyclosporine and mycophe-
nolate mofetil for GVHD prophylaxis, with acute GVHD
presenting a little over one week from the scheduled taper of
the mycophenolate mofetil. In all circumstances, the subse-
quenthospitalcoursewascomplicatedbymultipleinfections
andprotractedmanagementofsteroidresistantacuteGVHD
and in two of the patients, nosocomial transmission was
suspected.
3. Discussion
In the majority of these allogeneic stem cell transplant
patients, the presentation of adenovirus was late in the
GVHD course with fulminant presentation noted in our
sentinel patient as well as in two other individuals with
respiratory failure. Three patients survived the adenovirus
infection although all required very protracted hospi-
tal courses, one subsequently died of complications of
GVHD and in another of these patients, cidofovir-associated
encephalopathy became the major complicating condition.
Dosing schedules were altered in three of the patients due
to nephrotoxicity issues. Successful clearance of adenovirus
was only identiﬁed in one patient while in the two surviving
patients, adenovirus remained persistently detectable in
urine samples consistent with chronic viral cystitis. In
all cases, adenovirus was diﬃcult to diagnose due to the
complexity of the multiorgan disease processes seen in these
allogeneic transplant patients. The presenting symptoms
were often mimicked by other infections or by clinically
active acute GVHD [9]. The only survivors to date had
been detected relatively early in the viral presentation but
still experienced severe morbidity. One patient subsequently
died of complications of chronic GVHD and the other
two survivors currently have an unclear future. Notably,
in some of these patients, nosocomial transmission was
considered as a possible source. In patient 1, the virus
infection coincided with a community outbreak, although
it never was determined if his infection was of the same
viral strain. In patients 2 and 6, viral infection was identiﬁed
after patient 4 had experienced prolonged hospitalization
for her original presentation with adenovirus cystitis. As a
consequence, we feel aggressive infection control isolation
procedures with droplet and bodily ﬂuid isolation should be
implemented in all patients diagnosed with adenovirus and
have implemented this policy.
What clearly has been beneﬁcial is the development
and access to sensitive quantitative PCR assays that were
used in the early detection and for serial determinations
of adenovirus in these patients with advanced GVHD. New
algorithms for utilization of these extremely sensitive molec-
ular tools in this allogeneic transplant setting as screening
toolsmayprovetobecriticalinalteringthenaturalhistoryof
disseminated adenovirus in this immune-suppressed patient
population [10–12].
Treatment for adenovirus in hematopoietic stem cell
transplant patients is challenging for multiple reasons. As
discussed above, diagnosis may be delayed due to con-
founding picture with GVHD and/or coinfections. Once
adenovirus is suspected either by clinical history or non
conﬁrmatory diagnostic test, often the treatment with cid-
ofovir is delayed until conﬁrmatory tests have been done
due to reluctance of clinicians to use the drug due to its
severe side eﬀect proﬁle including renal toxicity and CNS
side eﬀects. Extrapolation of these data would suggest that if
there was a less toxic drug for the treatment of adenovirus,
utilization would be more likely to occur earlier in the
infectious time course, thereby decreasing morbidity and
mortality.
Currently, a new agent that meets this description is
being assessed in phase 2 clinical trials across the country.
CMX001 is an oral lipid conjugate of cidofovir [13]. This
medication has been shown to have eﬀectiveness against all
double stranded DNA viruses which includes herpesviruses
(CMV, HSV-1 and -2, VZV, EBV, HHV-6, and HHV-8),
adenoviruses(AdV3,AdV5,AdV7,AdV8,andAdV31),poly-
omaviruses (BKV and JC virus), orthopoxviruses (variola,
monkeypox, vaccinia, cowpox, and ectromelia viruses), and
papillomaviruses (HPV). Advantages include potent activity
againstalldsDNAviruses,goodoralbioavailability,potential
safety given decreased dosing and increased potency, and
lack of concentration in the kidney epithelial tubule cells.
As this case series reﬂects, a medication that can be used
safely for the treatment of localized and/or disseminated
adenovirus will be a major advancement; however the GI
toxicity often associated with acute GVHD may compromise
the oral absorption of the medication. If the promise of this
agent materializes without demonstration of a serious side
eﬀect proﬁle, one can even imagine institution of the agent
as prophylaxis against these viruses and could prove to be
of beneﬁt in the hematopoietic stem cell transplant patient
population.
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